Please cancel claims 61-64.

Please add the claims as follows:

- 60) (Amended) A parenteral therapeutic agent for the treatment of bacterial infections caused by Clostridium, said parenteral therapeutic agent produced by the method of:
 - (a) obtaining an effective amount of at least one enzyme genetically coded for by bacteriophage specific for a specific [bacteria] <u>Clostridium species</u>, wherein said at least one enzyme is selected from the group consisting of lytic enzymes, shuffled lytic enzymes, chimeric lytic enzymes, holin lytic enzymes, and combinations thereof, said at least one enzyme having the ability to digest a cell wall of a specific said [bacteria] <u>specific</u> <u>Clostridium species</u>; and,
- (b) mixing (a) with a carrier for the parenteral delivery of said at least one lytic enzyme to the site of the infection.
- 78) (Amended) The parenteral therapeutic agent according to claim 60, wherein the therapeutic agent further comprises at least one complementary agent which potentiates the bactericidal activity of the lysine enzyme, said complementary agent being selected from the group consisting of penicillin, synthetic penicillins bacitracin, methicillin, cephalosporin, polymyxin,